Recombinant SLAMblind Measles Virus Is a Promising Candidate for Nectin-4-Positive Triple Negative Breast Cancer Therapy

MLA

Tomoko Fujiyuki, et al. “Recombinant SLAMblind Measles Virus Is a Promising Candidate for Nectin-4-Positive Triple Negative Breast Cancer Therapy.” Molecular Therapy Oncolytics, vol. 19, Feb. 2020. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....5c1b53e4a96f9cef09c53fe63b0ac7f2&authtype=sso&custid=ns315887.

APA

Tomoko Fujiyuki, Hiroki Sato, Mutsumi Awano, Misako Yoneda, Yosuke Amagai, Akihiro Sugai, Koichiro Shoji, Shosaku Hattori, Takeshi Kuraishi, & Chieko Kai. (2020). Recombinant SLAMblind Measles Virus Is a Promising Candidate for Nectin-4-Positive Triple Negative Breast Cancer Therapy. Molecular Therapy Oncolytics, 19.

Chicago

Tomoko Fujiyuki, Hiroki Sato, Mutsumi Awano, Misako Yoneda, Yosuke Amagai, Akihiro Sugai, Koichiro Shoji, Shosaku Hattori, Takeshi Kuraishi, and Chieko Kai. 2020. “Recombinant SLAMblind Measles Virus Is a Promising Candidate for Nectin-4-Positive Triple Negative Breast Cancer Therapy.” Molecular Therapy Oncolytics 19 (February). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....5c1b53e4a96f9cef09c53fe63b0ac7f2&authtype=sso&custid=ns315887.